Yusuke Nakamura to Drug Screening Assays, Antitumor
This is a "connection" page, showing publications Yusuke Nakamura has written about Drug Screening Assays, Antitumor.
Connection Strength
0.325
-
A unique hinge binder of extremely selective aminopyridine-based Mps1 (TTK) kinase inhibitors with cellular activity. Bioorg Med Chem. 2015 May 01; 23(9):2247-60.
Score: 0.129
-
Identification of candidate predictive markers of anticancer drug sensitivity using a panel of human cancer cell lines. Cancer Sci. 2003 Dec; 94(12):1074-82.
Score: 0.059
-
Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene. 2003 Apr 10; 22(14):2192-205.
Score: 0.056
-
Anti-myeloma activity of MELK inhibitor OTS167: effects on drug-resistant myeloma cells and putative myeloma stem cell replenishment of malignant plasma cells. Blood Cancer J. 2016 08 19; 6(8):e460.
Score: 0.036
-
Discovery of imidazo[1,2-b]pyridazine derivatives: selective and orally available Mps1 (TTK) kinase inhibitors exhibiting remarkable antiproliferative activity. J Med Chem. 2015 Feb 26; 58(4):1760-75.
Score: 0.032
-
An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res. 2002 Feb 15; 62(4):1139-47.
Score: 0.013